• Global medical experts gather for 2016 ECHO Summit

    Dr. Nassir Ghaemi of Tufts Medical Center in Boston

    Dr. Nassir Ghaemi of Tufts Medical Center in Boston

    OVER 1,000 Filipino medical practitioners gathered for the 2016 Experts’ Convergence for Health Outcomes (ECHO) Summit at the Marriott Hotel Grand Ballroom in Pasay City to obtain new knowledge and insights on the latest trends from four internationally acclaimed experts in different medical fields.

    Dr. Ma. Rosario Sevilla, one of the members of the organizing committee, said this year’s ECHO Summit focused on the topics of depression, women’s health, diabetes, and cardiovascular disease.

    Joining the summit were four world-renowned speakers namely Dr. Nassir Ghaemi, a professor at the Department of Psychiatry, Tufts Medical Center in Boston; Dr. Amos Pines, associate professor at the Sackler Faculty of Medicine in Tel-Aviv University in Israel; Dr. Wilfred Fujimoto, professor emeritus of internal medicine at the University of Washington; and Dr. Bertram Pitt, a professor emeritus of medicine at the University of Michigan.

    Dr. Ghaemi talked about depression and anxiety as risk factors for cardiovascular diseases and presented studies that examine whether treatment using antidepressants improves cardiovascular outcomes in depressed patients.

    Dr. Wilfred Fujimoto of University of Washington

    Dr. Wilfred Fujimoto of University of Washington

    Meanwhile, Dr. Pines discussed the increased incidence of cardiovascular disease in women after menopause. The expert also tackled the potential benefits of hormone replacement therapy in reducing the risk of coronary heart disease and bone loss among menopausal women.

    Dr. Fujimoto, for his part, shared his team’s findings on a study which explored diabetes in Japanese-Americans. He said Japanese-Americans who live in the US are even more susceptible to diabetes than the Japanese who are living in Tokyo.

    Lastly, Dr. Pitt presented the latest trends in the use of mineralocorticoid receptor antagonists (MRAs), such as spironolactone and eplerenone in the management of heart failure as well as new drug agents which can help manage the hyperkalemia, which often accompanies the use of MRAs.


    Please follow our commenting guidelines.

    1 Comment

    1. Jay Trennoche on

      Notice that the article nor the medical people involved even mention prevention?

      It is always the same thing…more chemicals as a treatment; chemicals that do not remove the problem or cause of the disease but interact in the perpetuation of the disease.

      Why isn’t some of all that money they control and drug sales they profit from ever invested in the cause and the prevention of all these diseases.

      We realize it is difficult to turn ones back on large easy profits and; difficult to change the course or direction of business…for big business is surely what disease care is.

      Thank you,